Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01522976
Show Display Options
Rank Status Study
1 Active, not recruiting Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Conditions: Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts;   Secondary Myelodysplastic Syndrome
Interventions: Drug: Azacitidine;   Drug: Lenalidomide;   Drug: Vorinostat

Indicates status has not been verified in more than two years